Founded in 1995, Mankind Pharma Limited has emerged as a leading player in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of diverse pharmaceutical formulations across acute and chronic therapeutic segments. Additionally, the company offers a range of consumer healthcare products.
In this article, we delve into the comprehensive profile of Mankind Pharma Limited, exploring its journey, key achievements, product portfolio, market presence, and impact within the healthcare sector. Join us as we uncover everything you need to know about this dynamic and innovative pharmaceutical company.
About Mankind Pharma
Mankind Pharma Limited has established itself as a dominant force in the Indian pharmaceutical market, boasting impressive leadership rankings and a robust presence in various therapeutic segments. Over the last five years, the company has consistently held the top position in prescriptions and secured the distinction of being the youngest among the top five players in the Indian Pharmaceutical Market (IPM). Mankind Pharma is ranked fourth by value in the IPM and has achieved significant market success with four consumer healthcare brands leading their respective categories. The company’s focus on acute and chronic therapeutic areas such as anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory has yielded remarkable results, especially evident in its outperformance in chronic therapies during the 9MFY24.
Mankind Pharma’s sales mix in Q3FY24 highlights its diversified portfolio, with significant contributions from anti-infectives, cardiovascular, gastrointestinal, and respiratory segments. The company’s extensive brand portfolio includes several leading brands like Manforce (Rx), Moxikind-CV, Amlokind-AT, and Unwanted-Kit, among others, many of which have achieved substantial domestic sales figures exceeding ₹200 crores. With 22 brands surpassing the ₹100 crore mark, Mankind Pharma continues to demonstrate its prowess and innovation in the pharmaceutical industry.
How to Purchase Mankind Pharma?
Below are the trading platforms that you can use to purchase Mankind Pharma shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| April 2024 | 2,527.20 | 2,197.57 |
| May 2024 | 2,489.85 | 2,165.09 |
| June 2024 | 2,579.49 | 2,243.03 |
| July 2024 | 2,553.69 | 2,220.60 |
| August 2024 | 2,655.84 | 2,309.43 |
| September 2024 | 2,762.07 | 2,401.80 |
| October 2024 | 2,707.91 | 2,354.71 |
| November 2024 | 2,789.15 | 2,425.35 |
| December 2024 | 2,858.88 | 2,485.98 |
Mankind Pharma’s share price outlook for 2024 appears promising, with a projected increase in the range throughout the year. The stock’s maximum target by December 2024 is ₹2,858.88, while the minimum target stands at ₹2,485.98, indicating a potentially steady upward trend. The current share price of ₹2,340 (as of April 4th, 2024) is expected to align with this trajectory, supported by a robust market capitalization of ₹93,736 crore.
Despite the stock’s high P/E ratio of 56.8, Mankind Pharma demonstrates strong financial performance with a healthy return on capital employed (ROCE) of 20.7% and a return on equity (ROE) of 17.0%. The stock’s book value of ₹216 and a face value of ₹1.00 underscore its sound fundamentals, making Mankind Pharma an attractive proposition for investors seeking growth potential in the pharmaceutical sector.
| When | Maximum Price | Minimum Price |
| January 2025 | 2,916.06 | 2,243.12 |
| February 2025 | 2,990.83 | 2,300.64 |
| March 2025 | 3,107.47 | 2,390.36 |
| April 2025 | 3,046.54 | 2,343.49 |
| May 2025 | 2,957.81 | 2,275.24 |
| June 2025 | 3,090.91 | 2,377.62 |
| July 2025 | 3,030.30 | 2,331.00 |
| August 2025 | 3,124.02 | 2,403.09 |
| September 2025 | 3,233.36 | 2,487.20 |
| October 2025 | 3,317.43 | 2,551.87 |
| November 2025 | 3,400.37 | 2,615.67 |
| December 2025 | 3,485.38 | 2,681.06 |
Mankind Pharma’s share price outlook for 2025 suggests a positive trajectory with anticipated growth throughout the year. The projected maximum target by December 2025 is ₹3,485.38, while the minimum target is ₹2,243.12 in January, reflecting potential upward momentum. This outlook aligns with the company’s strategic focus to enhance prescription value in existing strong markets by expanding coverage and increasing presence in the chronic segment, including therapies like Diabetes (Insulin Glargine) and Respiratory (Inhalers), with plans to venture into new areas like CNS, Transplant, Urology, and Oncology.
Mankind Pharma also aims to strengthen its footprint in metros and Tier I cities while expanding its international presence through high-quality API offerings at competitive Indian prices and advancing its consumer healthcare business. These initiatives are likely to drive growth and support the positive trajectory of the company’s share price in 2025.
| When | Maximum Price | Minimum Price |
| January 2026 | 3,589.94 | 2,761.49 |
| February 2026 | 3,681.99 | 2,832.30 |
| March 2026 | 3,825.58 | 2,942.76 |
| April 2026 | 3,750.57 | 2,885.06 |
| May 2026 | 3,641.33 | 2,801.03 |
| June 2026 | 3,805.19 | 2,927.07 |
| July 2026 | 3,730.58 | 2,869.68 |
| August 2026 | 3,845.96 | 2,958.43 |
| September 2026 | 3,980.57 | 3,061.98 |
| October 2026 | 4,084.06 | 3,141.59 |
| November 2026 | 4,186.17 | 3,220.13 |
| December 2026 | 4,290.82 | 3,300.63 |
Mankind Pharma’s share price forecast for 2026 demonstrates a bullish trend, with projected maximum targets reaching as high as ₹4,290.82 by December and minimum targets around ₹2,761.49 in January. This upward trajectory aligns with the company’s strategic initiatives, including expanding exports to various countries beyond the USA, such as Sri Lanka, Nepal, Chile, and Kenya.
Additionally, Mankind Pharma’s investment in capital expenditures (capex) totaled approximately ₹324 crores in the first nine months of FY24, indicating a strategic allocation of resources to support future growth and innovation. The forecasted share price growth reflects investor confidence in Mankind Pharma’s expansion strategies and global market presence, underscoring the company’s potential for sustained growth in the pharmaceutical sector.
| When | Maximum Price | Minimum Price |
| January 2027 | 4,376.64 | 3,366.64 |
| February 2027 | 4,488.86 | 3,452.97 |
| March 2027 | 4,663.92 | 3,587.63 |
| April 2027 | 4,572.47 | 3,517.29 |
| May 2027 | 4,439.29 | 3,414.84 |
| June 2027 | 4,639.06 | 3,568.51 |
| July 2027 | 4,548.10 | 3,498.54 |
| August 2027 | 4,688.76 | 3,606.74 |
| September 2027 | 4,852.87 | 3,732.98 |
| October 2027 | 4,979.04 | 3,830.03 |
| November 2027 | 5,103.52 | 3,925.79 |
| December 2027 | 5,231.11 | 4,023.93 |
Mankind Pharma’s share price projections for 2027 indicate a robust upward trajectory, with expected maximum targets reaching as high as ₹5,231.11 by December and minimum targets around ₹3,366.64 in January.
In addition to its financial outlook, Mankind Pharma has leveraged its brand strength through strategic endorsements. The company’s corporate ambassadors include Amitabh Bachchan, Mohanlal, and Vijay Sethupathi, while consumer healthcare brands are represented by Karthik Aryan, Sunny Leone, Anushka Sharma, Rashi Khanna, Mahesh Babu, and Ranveer Singh, among others. These partnerships underscore Mankind Pharma’s commitment to brand visibility and market engagement, contributing to its overall success in the pharmaceutical and consumer healthcare sectors.
| When | Maximum Price | Minimum Price |
| January 2028 | 5,335.73 | 4,104.41 |
| February 2028 | 5,472.54 | 4,209.65 |
| March 2028 | 5,685.97 | 4,373.83 |
| April 2028 | 5,574.48 | 4,288.06 |
| May 2028 | 5,412.12 | 4,163.17 |
| June 2028 | 5,655.67 | 4,350.51 |
| July 2028 | 5,544.77 | 4,265.21 |
| August 2028 | 5,716.26 | 4,397.12 |
| September 2028 | 5,916.33 | 4,551.02 |
| October 2028 | 6,070.15 | 4,669.35 |
| November 2028 | 6,221.91 | 4,786.08 |
| December 2028 | 6,377.45 | 4,905.73 |
- January 2028: ₹4,104.41 (Minimum)
- December 2028: ₹6,377.45 (Maximum)
| When | Maximum Price | Minimum Price |
| January 2029 | 6,505.00 | 5,003.85 |
| February 2029 | 6,671.80 | 5,132.15 |
| March 2029 | 6,932.00 | 5,332.31 |
| April 2029 | 6,796.08 | 5,227.75 |
| May 2029 | 6,598.13 | 5,075.49 |
| June 2029 | 6,895.05 | 5,303.88 |
| July 2029 | 6,759.85 | 5,199.89 |
| August 2029 | 6,968.92 | 5,360.71 |
| September 2029 | 7,212.83 | 5,548.33 |
| October 2029 | 7,400.36 | 5,692.59 |
| November 2029 | 7,585.37 | 5,834.90 |
| December 2029 | 7,775.01 | 5,980.78 |
- January 2029: ₹5,003.85(Minimum)
- December 2029: ₹7,775.01 (Maximum)
| When | Maximum Price | Minimum Price |
| January 2030 | 7,930.51 | 6,100.39 |
| February 2030 | 8,133.85 | 6,256.81 |
| March 2030 | 8,451.07 | 6,500.83 |
| April 2030 | 8,285.37 | 6,373.36 |
| May 2030 | 8,044.05 | 6,187.73 |
| June 2030 | 8,406.03 | 6,466.18 |
| July 2030 | 8,241.20 | 6,339.39 |
| August 2030 | 8,496.09 | 6,535.45 |
| September 2030 | 8,793.45 | 6,764.19 |
| October 2030 | 9,022.08 | 6,940.06 |
| November 2030 | 9,247.63 | 7,113.56 |
| December 2030 | 9,478.82 | 7,291.40 |
- January 2030: ₹6,100.39 (Minimum)
- December 2030: ₹9,478.82 (Maximum)
Financial Condition of Mankind Pharma: Last 5 Years
| Financials | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Sales (Rs. Crores) | 3,829 | 4,794 | 5,523 | 7,486 | 8,127 |
| Expenses (Rs. Crores) | 3,124 | 3,550 | 4,151 | 5,644 | 6,429 |
| Operating Profit | 705 | 1,244 | 1,372 | 1,842 | 1,698 |
| Other Income (Rs. Crores) | 64 | 94 | 154 | 200 | 163 |
| Interest (Rs. Crores) | 40 | 11 | 8 | 48 | 28 |
| Depreciation (Rs. Crores) | 38 | 62 | 78 | 123 | 270 |
| Profit Before Tax (Rs. Crores) | 691 | 1,265 | 1,440 | 1,871 | 1,563 |
| Net Profit (Rs. Crores) | 514 | 958 | 1,084 | 1,389 | 1,248 |
| EPS (Rs.) | 12.83 | 23.92 | 27.07 | 34.68 | 31.16 |
| Dividend Payout (%) | 0 | 32 | 0 | 0 | 0 |
- Over the past five years, Mankind Pharma has demonstrated impressive financial growth, with substantial increases in sales and profitability.
- The company’s sales surged from ₹3,829 crores in 2019 to ₹8,127 crores in 2023, reflecting a robust compounded sales growth rate of 16% over this period.
- Operating profit showed consistent growth, rising from ₹705 crores in 2019 to ₹1,698 crores in 2023.
- Mankind Pharma’s net profit increased steadily from ₹514 crores in 2019 to ₹1,248 crores in 2023, translating to a compounded profit growth rate of 12% over the last five years.
- Earnings per share (EPS) witnessed significant growth, reaching ₹31.16 in 2023 from ₹12.83 in 2019.
- Despite strong financial performance, the company maintained a conservative dividend payout policy with no payouts in the last five years.
- Return on equity (ROE) remained resilient at 22% over the past five years, indicating efficient utilization of shareholders’ funds.
- The last year’s ROE stood at 17%, showcasing Mankind Pharma’s ability to generate favorable returns for shareholders amidst changing market dynamics.
FAQs
What is Mankind Pharma’s current market capitalization?
Mankind Pharma’s current market capitalization is ₹93,736 crore.
The current share price target for Mankind Pharma varies depending on the month, with a maximum target of ₹2,858.88 (December 2024) and a minimum target of ₹2,197.57 (April 2024).
The projected share price target for Mankind Pharma in 2025 ranges from a maximum of ₹3,485.38 (December 2025) to a minimum of ₹2,243.12 (January 2025).
Mankind Pharma’s projected share price target for 2030 ranges from a maximum of ₹9,478.82 (December 2030) to a minimum of ₹6,100.39 (January 2030).
What is Mankind Pharma’s current price-to-earnings (P/E) ratio?
Mankind Pharma’s current P/E ratio is 56.8.
What is Mankind Pharma’s dividend payout percentage?
Mankind Pharma has maintained a conservative dividend payout policy, with no payouts in the last five years.
How has Mankind Pharma’s sales grown over the past decade?
Mankind Pharma has achieved a compounded sales growth rate of 10% over the past decade.
What has been Mankind Pharma’s compounded profit growth rate over the last five years?
Mankind Pharma’s compounded profit growth rate over the last five years has been 12%.
Also Read
Conclusion: Mankind Pharma’s Growth Trajectory and Investment Outlook
In conclusion, Mankind Pharma Limited has emerged as a prominent player in the pharmaceutical industry, characterized by robust financial performance and a diversified product portfolio. Over the past five years, the company has exhibited remarkable growth in sales, operating profit, and net profit, reflecting a compounded sales growth rate of 16%. This growth trajectory underscores Mankind Pharma’s effective market strategies and a strong presence across therapeutic segments like anti-infectives, cardiovascular, gastrointestinal, and respiratory, supported by a lineup of successful brands.
Mankind Pharma’s strategic focus on chronic therapeutic areas and expansion into new segments like Diabetes and Respiratory therapy bodes well for its future growth prospects. The company’s commitment to innovation is evident through its investment in capital expenditures (capex) to drive research, development, and international expansion. Moreover, Mankind Pharma’s brand visibility and market engagement, highlighted by strategic endorsements and a robust market capitalization of ₹93,736 crore, reinforce its leading position in the pharmaceutical sector.
Despite strong financial performance, it’s noteworthy that Mankind Pharma has chosen to retain earnings, as indicated by a conservative dividend payout policy. Additionally, the stock’s current price-to-earnings (P/E) ratio of 56.8 and trading at 10.8 times its book value suggest a premium valuation. Investors seeking growth potential in the pharmaceutical sector might find Mankind Pharma an attractive proposition given its consistent profitability and debt reduction but should consider the absence of dividend payouts and premium valuation as part of their investment evaluation.
What did we learn?
- 1 About Mankind Pharma
- 2 How to Purchase Mankind Pharma?
- 3 Mankind Pharma Share Price Prediction 2024 – 2030
- 4 Financial Condition of Mankind Pharma: Last 5 Years
- 5 FAQs
- 5.1 What is Mankind Pharma’s current market capitalization?
- 5.2 What is the current share price target for Mankind Pharma?
- 5.3 What is Mankind Pharma’s projected share price target for 2025?
- 5.4 What is Mankind Pharma’s projected share price target for 2030?
- 5.5 What is Mankind Pharma’s current price-to-earnings (P/E) ratio?
- 5.6 What is Mankind Pharma’s dividend payout percentage?
- 5.7 How has Mankind Pharma’s sales grown over the past decade?
- 5.8 What has been Mankind Pharma’s compounded profit growth rate over the last five years?
- 6 Conclusion: Mankind Pharma’s Growth Trajectory and Investment Outlook
